Phase Ib Open Label, Randomized, Controlled, Dose-Escalation Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Volunteers in South Africa.
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2013
At a glance
- Drugs BCG vaccine (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 18 Nov 2011 Actual end date (March 2011) added as reported by ClinicalTrials.gov.
- 18 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.